Abstract
Porphyrias are metabolic disorders due to deficiencies of specific enzymes of the heme biosynthetic pathway. They are associated with striking accumulations and excess excretion of heme pathway intermediates and their oxidized products. Symptoms and signs are almost all due to effects on the nervous system or skin. The three most common porphyrias, acute intermittent porphyria, porphyria cutanea tarda and erythropoietic protoporphyria, differ considerably from each other. The first presents with acute neurovisceral symptoms and can be aggravated by some drugs. Its treatment comprises intravenous heme administration and liberal amounts of glucose. In the latter two porphyrias the skin is affected, though with different lesions. Treatment differs also, from reducing excess iron for the first, and administration of β-carotene for the last porphyria. These disorders are more often manifest in adults than are most metabolic diseases. All porphyrias are inherited, with the exception of porphyria cutanea tarda, which is due to an acquired enzyme deficiency in liver, although an inherited deficiency is a predisposing factor in some cases.
Access this chapter
Tax calculation will be finalised at checkout
Purchases are for personal use only
Preview
Unable to display preview. Download preview PDF.
References
Granick S (1966) The induction in vitro of the synthesis of 6-aminolevulinic acid synthetase in chemical porphyria: a response to certain drugs, sex hormones, and foreign chemicals. J Biol Chem 241: 1359–1375
Anderson KE, Freddara U, Kappas A (1982) Induction of hepatic cytochrome P-450 by natural steroids: relationships to the induction of 6-aminolevulinate synthase and porphyrin accumulation in the avian embryo. Arch Biochem Biophys 17: 597–608
Anderson KE (1996) The porphyrias (Chapter 14). In: Zakim D, Boyer T, (ed) Hepatology. Philadelphia, W.B. Saunders Co 417–463
Anderson KE (2000) The porphyrias. In: Goldman L, Bennett CJ (ed) Cecil Textbook of Medicine. Philadelphia, W.B. Saunders Co. 1123–1132
Poh-Fitzpatrick MB (1976) Lamola AA. Direct spectrophotometry of diluted erythrocytes and plasma: a rapid diagnostic method in primary and secondary porphyrinemias. J Lab Clin Med 87: 362–370
Poh-Fitzpatrick MB (1980) A plasma porphyrin fluorescence marker for variegate porphyria. Arch Dermatol 116: 543–547
Shimizu Y, Ida S, Naruto H, Urata G (1978) Excretion of porphyrins in urine and bile after the administration of deltaaminolevulinic acid. J Lab Clin Med 92: 795–802
Sassa S (1998) ALAD porphyria. Semin Liver Dis 18: 95–101
Kauppinen R, Mustajoki P (1992) Prognosis of acute porphyria: occurrence of acute attacks, precipitating factors, and associated diseases. Medicine 71: 1–13
Andant C, Puy H, Faivre J, Deybach JC (1998) Acute hepatic porphyrias and primary liver cancer [letter]. N Engl J Med 338: 1853–4
Grandchamp B (1998) Acute intermittent porphyria. Semin Liver Dis 18: 17–24
Tenhunen R, Mustajoki P (1998) Acute porphyria: treatment with heme. Semin Liver Dis 18: 53–5
Bonkovsky HL, Healey BS, Lourie AN, Gerron GG (1991) Intravenous heme-albumin in acute intermittent porphyria: evidence for repletion of hepatic hemoproteins and regulatory heure pools. Am J Gastroenterol 86: 1050–1056
Anderson KE, Spitz IM, Bardin CW, Kappas A (1990) A GnRH analogue prevents cyclical attacks of porphyria. Arch Int Med 150: 1469–1474
Hahn M, Gildemeister OS, Krauss GL et al. (1997) Effects of new anticonvulsant medications on porphyrin synthesis in cultured liver cells: potential implications for patients with acute porphyria. Neurology 49: 97–106
Verstraeten L, Van Regemorter N, Pardou A et al. (1993) Biochemical diagnosis of a fatal case of Gunther’s disease in a newborn with hydrops-fetalis. Eur J Clin Chem Clin Biochem 31: 121–128
Desnick RJ, Glass IA, Xu W, Solis C, Astrin KH (1998) 24. Molecular genetics of congenital erythropoietic porphyria. Semin Liver Dis 18: 77–84
Elder GH (1998) Porphyria cutanea tarda. Semin Liver Dis 25. 18: 67–75
Bonkovsky HL, Poh-Fitzpatrick M, Pimstone N et al. (1998) Porphyria cutanea tarda, hepatitis C, and HFE gene mutations in North America. Hepatology 27: 1661–1669
Sinclair PR, Gorman G, Shedlofsky SI et al. (1997) Ascorbic acid deficiency in porphyria cutanea tarda. J Lab Clin Med 27. 130: 197–201
Egger NG, Goeger DE, Anderson KE (1996) Effects of 28. chloroquine in hematoporphyrin-treated animals. ChemicoBiological Interactions 102: 69–78
Martasek P (1998) Hereditary coproporphyria. Semin Liver Dis 18: 25–32.
Kirsch RE, Meissner PN, Hift RJ (1998) Variegate porphyria. Semin Liver Dis 18: 33–41
Da Silva V, Simonin S, Deybach JC, Puy H, Nordmann Y (1995) Variegate porphyria• diagnostic value of fluorometric scanning of plasma porphyrins. Clin Chim Acta 238: 163–8
Cox TM, Alexander GJ, Sarkany RP (1998) Protoporphyria. Semin Liver Dis 18: 85–93
Lichtin A, Anderson K, Bloomer J et al. (1998) Correction of erythropoietic protoporphyria (EPP) phenotype by allogenic bone marrow transplant. American Society of Hematology Annual Meeting, December 7, 1998
Went LN, Klasen EC (1984) Genetic aspects of erythropoietic protoporphyria. Ann Hum Genet 48: 105–17
Wang X, Kurtz L, Bloomer J, Christiano A, Poh-Fitzpatrick M (1998). Haplotype analysis in four families with an exon skipping mutation in the ferrochelatase gene. J Invest Dermatol no: 618
Poh-Fitzpatrick MB, Piomelli S, Deybach J-C, Gouya W, Wang X (1997) Erythropoietic protoporphyria: a triallelic inheritance model. J Invest Dermatol 108: 598
Editor information
Editors and Affiliations
Rights and permissions
Copyright information
© 2000 Springer-Verlag Berlin Heidelberg
About this chapter
Cite this chapter
Egger, N.G., Goeger, D.E., Anderson, K.E. (2000). The Porphyrias. In: Fernandes, J., Saudubray, JM., Van den Berghe, G. (eds) Inborn Metabolic Diseases. Springer, Berlin, Heidelberg. https://doi.org/10.1007/978-3-662-04285-4_32
Download citation
DOI: https://doi.org/10.1007/978-3-662-04285-4_32
Publisher Name: Springer, Berlin, Heidelberg
Print ISBN: 978-3-662-04287-8
Online ISBN: 978-3-662-04285-4
eBook Packages: Springer Book Archive